135 related articles for article (PubMed ID: 31533096)
41. Oral versus intravenous iron supplementation in peritoneal dialysis patients.
Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
Perit Dial Int; 2001; 21 Suppl 3():S231-5. PubMed ID: 11887827
[TBL] [Abstract][Full Text] [Related]
42. Anaemia of prematurity: treatment with erythropoietin.
Carbonell-Estrany X; Figueras-Aloy J
Early Hum Dev; 2001 Nov; 65 Suppl():S63-7. PubMed ID: 11755036
[TBL] [Abstract][Full Text] [Related]
43. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
Zhang Y; Xiao C; Gu SC; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
[TBL] [Abstract][Full Text] [Related]
44. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
Verhoef GE; Zachée P; Ferrant A; Demuynck H; Selleslag D; Van Hove L; Deckers F; Boogaerts MA
Ann Hematol; 1992 Jan; 64(1):16-21. PubMed ID: 1739754
[TBL] [Abstract][Full Text] [Related]
45. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
Mohr B; Herrmann R; Huhn D
Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
[TBL] [Abstract][Full Text] [Related]
46. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
[TBL] [Abstract][Full Text] [Related]
47. Recombinant human erythropoietin in patients with inflammatory bowel disease and refractory anemia: a 15-year single center experience.
Katsanos KH; Tatsioni A; Natsi D; Sigounas D; Christodoulou DK; Tsianos EV
J Crohns Colitis; 2012 Feb; 6(1):56-61. PubMed ID: 22261528
[TBL] [Abstract][Full Text] [Related]
48. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients.
Kalantar-Zadeh K; McAllister CJ; Lehn RS; Lee GH; Nissenson AR; Kopple JD
Am J Kidney Dis; 2003 Oct; 42(4):761-73. PubMed ID: 14520627
[TBL] [Abstract][Full Text] [Related]
49. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
[TBL] [Abstract][Full Text] [Related]
50. Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study.
Ciudin A; Simó-Servat O; Balibrea JM; Vilallonga R; Hernandez C; Simó R; Mesa J
Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):17-20. PubMed ID: 29233512
[TBL] [Abstract][Full Text] [Related]
51. Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes.
Deshet-Unger N; Oster HS; Prutchi-Sagiv S; Maaravi N; Golishevski N; Neumann D; Mittelman M
Leuk Res; 2017 Jan; 52():20-27. PubMed ID: 27870945
[TBL] [Abstract][Full Text] [Related]
52. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
53. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
54. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
56. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study.
Ohls RK; Harcum J; Schibler KR; Christensen RD
J Pediatr; 1997 Nov; 131(5):661-5. PubMed ID: 9403642
[TBL] [Abstract][Full Text] [Related]
57. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
[TBL] [Abstract][Full Text] [Related]
58. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
59. Oral iron supplementation in preterm infants treated with erythropoietin.
Fujiu T; Maruyama K; Koizumi T
Pediatr Int; 2004 Dec; 46(6):635-9. PubMed ID: 15660859
[TBL] [Abstract][Full Text] [Related]
60. Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.
Zuccarini A; Cicognini D; Tancredi R; Ferrari A; Rizzo G; Lasagna A; Caccialanza R; Cavanna L; Orlandi E; Biasini C; Molinaro P; Garigliano D; Costantino A; Moroni M; Perrone L; Alessio NL; Rovati B; Ferretti VV; Klersy C; Pedrazzoli P
Support Care Cancer; 2022 Sep; 30(9):7645-7653. PubMed ID: 35678882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
